Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset
- Author:
Ki Hyeong LEE
1
;
Byoung Chul CHO
;
Myung-Ju AHN
;
Yun-Gyoo LEE
;
Youngjoo LEE
;
Jong-Seok LEE
;
Joo-Hang KIM
;
Young Joo MIN
;
Gyeong-Won LEE
;
Sung Sook LEE
;
Kyung-Hee LEE
;
Yoon Ho KO
;
Byoung Yong SHIM
;
Sang-We KIM
;
Sang Won SHIN
;
Jin-Hyuk CHOI
;
Dong-Wan KIM
;
Eun Kyung CHO
;
Keon Uk PARK
;
Jin-Soo KIM
;
Sang Hoon CHUN
;
Jangyoung WANG
;
SeokYoung CHOI
;
Jin Hyoung KANG
Author Information
- Publication Type:Original Article
- From:Cancer Research and Treatment 2024;56(1):48-60
- CountryRepublic of Korea
- Language:EN
-
Abstract:
Purpose:This subgroup analysis of the Korean subset of patients in the phase 3 LASER301 trial evaluated the efficacy and safety of lazertinib versus gefitinib as first-line therapy for epidermal growth factor receptor mutated (EGFRm) non–small cell lung cancer (NSCLC).
Materials and Methods:Patients with locally advanced or metastatic EGFRm NSCLC were randomized 1:1 to lazertinib (240 mg/day) or gefitinib (250 mg/day). The primary endpoint was investigator-assessed progression-free survival (PFS).
Results:In total, 172 Korean patients were enrolled (lazertinib, n=87; gefitinib, n=85). Baseline characteristics were balanced between the treatment groups. One-third of patients had brain metastases (BM) at baseline. Median PFS was 20.8 months (95% confidence interval [CI], 16.7 to 26.1) for lazertinib and 9.6 months (95% CI, 8.2 to 12.3) for gefitinib (hazard ratio [HR], 0.41; 95% CI, 0.28 to 0.60). This was supported by PFS analysis based on blinded independent central review. Significant PFS benefit with lazertinib was consistently observed across predefined subgroups, including patients with BM (HR, 0.28; 95% CI, 0.15 to 0.53) and those with L858R mutations (HR, 0.36; 95% CI, 0.20 to 0.63). Lazertinib safety data were consistent with its previously reported safety profile. Common adverse events (AEs) in both groups included rash, pruritus, and diarrhoea. Numerically fewer severe AEs and severe treatment–related AEs occurred with lazertinib than gefitinib.
Conclusion:Consistent with results for the overall LASER301 population, this analysis showed significant PFS benefit with lazertinib versus gefitinib with comparable safety in Korean patients with untreated EGFRm NSCLC, supporting lazertinib as a new potential treatment option for this patient population.
